Neuca S.a. stock
NEU.WAWSEHealthcareISIN PLTRFRM00018
60Score 60 out of 100, Neutral
Price and trend
47 / 100
Price history
−14% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.7% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 40).
The price is 18% below its 52-week high. Largest decline in 19 years: 70% (June 2007 to March 2009).
Chart figures for advanced users
- SMA 50$180.22
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$183.82
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)40
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$164.81
- The lowest closing price of the last twelve months.
- Resistance$213.88
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Neuca S.a. belongs to the Medical (Distribution) industry (Poland) and, with a market value of $792.08M, is number 16 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.43B (up 8.2% year on year) and earnings of $39.15M (up 0.9%).
- For fiscal 2026, analysts expect on average revenue of $3.67B (up 6.8%) and adjusted earnings per share of $11.40 (up 33.1%).
Show more
- MEQIRI Score 60 out of 100 (Neutral): rank 270 of 702 in Healthcare, median 53.
- The P/E is 16.5 (Medical (Distribution) median 26.8, own median of recent years 20.2).
- Our model puts fair value at $239.20, with the price 27% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 21 years.Capital allocation 65
- Modestly valuedP/E 16.5, Medical (Distribution) median 26.8, own median 20.2.Valuation 83
- Below fair valuePrice 27% below the fair value of $239.20.Valuation 83
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and valuation, while technical analysis and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 59 to 60.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $184.00 and expensive above $341.72 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $194.25 (cash-flow model) and $284.16 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 12.1%. At 13.1% the fair value would be $227.00, at 11.1% it would be $255.77.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (26.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 8.4% on the twelve months before. Revenue has grown solidly since 2006, at about 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 11%, operating 2%, net 1%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 19 Nov 2026in 6 days
- Last reported
- 26 Aug 2026EPS reported $2.23
Analyst estimates
- Earnings per share
- $11.40−1.3%
- Revenue
- $3.67B0.0%
- Earnings per share
- $13.57−3.6%
- Revenue
- $3.88B0.0%
MEQIRI has stored the estimates since 27 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Neuca S.a.
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 60
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- Asker Healthcare GroupASKER.ST $2.8B61
- Sopharma ADSPH.WA $1.88B57
- Redcare PharmacyRDC.DE $1.57B47
- UnipharUPR.IR $1.25B57
- Akso Health GroupAHG $1.15B35
- DocMorrisDOCM.SW $1.15B39
- ArjoARJO-B.ST $924.06M59
- MediosILM1.DE $315.41M50
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = PLN 3.9742)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 20 Jun 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.